{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:43:31Z","timestamp":1777934611667,"version":"3.51.4"},"reference-count":25,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Surgical Infections"],"published-print":{"date-parts":[[2023,3,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Current guidelines recommend a seven-day course of antibiotic therapy for patients with ventilator-associated pneumonia (VAP). However, clinical and microbiologic resolution of infection may occur much sooner than seven days, particularly in patients with early VAP. Shortening the course of antibiotic therapy for early VAP likely results in lower antibiotic-associated complications, but it is unclear whether VAP recurrence rates will be higher in patients receiving fewer days of therapy. We propose to compare four days versus seven days of antibiotic therapy for early VAP in surgical patients in a multicenter, pragmatic, randomized clinical trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>Eligible patients admitted to a surgical intensive care unit with early VAP, defined as VAP occurring within two to seven days of intubation, will be randomized to receive four or seven days of antibiotic therapy. The two primary outcomes are: VAP recurrence, defined as VAP occurring two to 14 days after completion of initial therapy and antibiotic-free days, defined as the number of days without receiving any antibiotic agents within 30 days from completion of initial therapy. Data will be analyzed using both intention-to-treat and per-protocol strategies. Power analysis was performed assuming non-inferiority of four days vs. seven days for VAP recurrence and superiority of four days versus seven days for antibiotic-free days. The total sample size to detect a 10% difference between groups with 80% power and assuming a 10% dropout rate is 458 patients. Three separate data analyses are planned throughout the trial and sample size will be re-calculated at each interim analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The Duration of Antibiotic Therapy for Early VAP (DATE) Trial will enroll surgical patients with early VAP to analyze whether a shorter duration of antibiotic therapy results in similar clinical outcomes while decreasing antibiotic exposure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/sur.2022.362","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T15:16:27Z","timestamp":1675350987000},"page":"163-168","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Duration of Antibiotic Therapy for Early VAP Trial: Study Protocol for a Surgical Infection Society Multicenter, Pragmatic, Randomized Clinical Trial of Four versus Seven Days of Definitive Antibiotic Therapy for Early Ventilator-Associated Pneumonia in Surgical Patients"],"prefix":"10.1177","volume":"24","author":[{"given":"Jonathan P.","family":"Meizoso","sequence":"first","affiliation":[{"name":"DeWitt Daughtry Family Department of Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA."},{"name":"Ryder Trauma Center, Jackson Memorial Hospital, Miami, Florida, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Sauaia","sequence":"additional","affiliation":[{"name":"Colorado School of Public Health, Aurora, Colorado, USA."},{"name":"Department of Surgery, University of Colorado Denver, Aurora, Colorado, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Namias","sequence":"additional","affiliation":[{"name":"DeWitt Daughtry Family Department of Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA."},{"name":"Ryder Trauma Center, Jackson Memorial Hospital, Miami, Florida, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald J.","family":"Manning","sequence":"additional","affiliation":[{"name":"DeWitt Daughtry Family Department of Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA."},{"name":"Ryder Trauma Center, Jackson Memorial Hospital, Miami, Florida, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fredric M.","family":"Pieracci","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Colorado Denver, Aurora, Colorado, USA."},{"name":"Ernest E. Moore Shock Trauma Center, Denver Health Medical Center, Denver, Colorado, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,2,28]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2013.01.002"},{"issue":"5","key":"e_1_3_5_3_2","first-page":"325","article-title":"Epidemiology of ICU-acquired pneumonia","volume":"24","author":"Ferrer M","year":"2018","unstructured":"Ferrer M, , Torres A. Epidemiology of ICU-acquired pneumonia. Curr Opin Crit Care, 2018; 24(5):325\u2013331; doi: 10.1097\/MCC.0000000000000536","journal-title":"Curr Opin Crit Care"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/TA.0000000000000425"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70081-1"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200405-644ST"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw353"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.19.2588"},{"issue":"6","key":"e_1_3_5_9_2","first-page":"1329","article-title":"Repeat bronchoalveolar lavage to guide antibiotic duration for ventilator-associated pneumonia","volume":"63","author":"Mueller EW","year":"2007","unstructured":"Mueller EW, , Croce MA, , Boucher BA, et al. Repeat bronchoalveolar lavage to guide antibiotic duration for ventilator-associated pneumonia. J Trauma. 2007; 63(6):1329\u20131337; doi: 10.1097\/TA.0b013e31812f6c46","journal-title":"J Trauma"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/TA.0b013e31825ac37b"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2014.086"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411162"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/tsaco-2022-000931"},{"key":"e_1_3_5_14_2","unstructured":"United States Food and Drug Administration. What is a Serious Adverse Event? 2016. Available from: https:\/\/www.fda.gov\/safety\/reporting-serious-problems-fda\/what-serious-adverse-event [Last accessed: November 3 2022]."},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-003-2018-2"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-199001000-00010"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.316.7139.1236"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2009.10.009"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2007.078"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix065"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2017.1938"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2007.04.001"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2009.10.001"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.257.5073.1064"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1086\/502091"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(06)70689-2"}],"container-title":["Surgical Infections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/sur.2022.362","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/sur.2022.362","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/sur.2022.362","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:29:31Z","timestamp":1777688971000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/sur.2022.362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,28]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3,1]]}},"alternative-id":["10.1089\/sur.2022.362"],"URL":"https:\/\/doi.org\/10.1089\/sur.2022.362","relation":{},"ISSN":["1096-2964","1557-8674"],"issn-type":[{"value":"1096-2964","type":"print"},{"value":"1557-8674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,28]]}}}